151 related articles for article (PubMed ID: 37393692)
1. Equivalence assessment of biotherapeutics with N- and O-glycosylation sites by sequential intact glycoform mass spectrometry (IGMS).
Oh MJ; Kim U; Kim S; Cho DS; Seo JA; Seo N; An HJ
J Pharm Biomed Anal; 2023 Sep; 234():115558. PubMed ID: 37393692
[TBL] [Abstract][Full Text] [Related]
2. Glycoform analysis of intact erythropoietin by MALDI FT-ICR mass spectrometry.
Lippold S; Thavarajah R; Reusch D; Wuhrer M; Nicolardi S
Anal Chim Acta; 2021 Nov; 1185():339084. PubMed ID: 34711323
[TBL] [Abstract][Full Text] [Related]
3. Mass spectrometric glycoform profiling of the innovator and biosimilar erythropoietin and darbepoetin by LC/ESI-MS.
Harazono A; Hashii N; Kuribayashi R; Nakazawa S; Kawasaki N
J Pharm Biomed Anal; 2013 Sep; 83():65-74. PubMed ID: 23708432
[TBL] [Abstract][Full Text] [Related]
4. Exposing the molecular heterogeneity of glycosylated biotherapeutics.
Schachner LF; Mullen C; Phung W; Hinkle JD; Beardsley MI; Bentley T; Day P; Tsai C; Sukumaran S; Baginski T; DiCara D; Agard NJ; Masureel M; Gober J; ElSohly AM; Melani R; Syka JEP; Huguet R; Marty MT; Sandoval W
Nat Commun; 2024 Apr; 15(1):3259. PubMed ID: 38627419
[TBL] [Abstract][Full Text] [Related]
5. [Recent advances in glycopeptide enrichment and mass spectrometry data interpretation approaches for glycoproteomics analyses].
Liu L; Qin H; Ye M
Se Pu; 2021 Oct; 39(10):1045-1054. PubMed ID: 34505426
[TBL] [Abstract][Full Text] [Related]
6. Innovative Metrics for Reporting and Comparing the Glycan Structural Profile in Biotherapeutics.
Mastrangeli R; Satwekar A; Bierau H
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110538
[TBL] [Abstract][Full Text] [Related]
7. Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry.
Zhu L; Guo Q; Guo H; Liu T; Zheng Y; Gu P; Chen X; Wang H; Hou S; Guo Y
MAbs; 2014; 6(6):1474-85. PubMed ID: 25484062
[TBL] [Abstract][Full Text] [Related]
8. Separation methods hyphenated to mass spectrometry for the characterization of the protein glycosylation at the intact level.
Camperi J; Pichon V; Delaunay N
J Pharm Biomed Anal; 2020 Jan; 178():112921. PubMed ID: 31671335
[TBL] [Abstract][Full Text] [Related]
9. Glycan analysis of erythropoiesis-stimulating agents.
Cowper B; Lavén M; Hakkarainen B; Mulugeta E
J Pharm Biomed Anal; 2020 Feb; 180():113031. PubMed ID: 31838284
[TBL] [Abstract][Full Text] [Related]
10. High-resolution glycoform profiling of intact therapeutic proteins by hydrophilic interaction chromatography-mass spectrometry.
Domínguez-Vega E; Tengattini S; Peintner C; van Angeren J; Temporini C; Haselberg R; Massolini G; Somsen GW
Talanta; 2018 Jul; 184():375-381. PubMed ID: 29674057
[TBL] [Abstract][Full Text] [Related]
11. Sensitive and comprehensive analysis of O-glycosylation in biotherapeutics: a case study of novel erythropoiesis stimulating protein.
Kim U; Oh MJ; Seo Y; Jeon Y; Eom JH; An HJ
Bioanalysis; 2017 Sep; 9(18):1373-1383. PubMed ID: 28920453
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis and characterization of glycan pairing in therapeutic antibodies and Fc-containing biotherapeutics: Addressing current limitations and implications for N-glycan impact.
Meudt M; Baumeister J; Mizaikoff B; Ebert S; Rosenau F; Blech M; Higel F
Eur J Pharm Biopharm; 2024 Jul; 200():114325. PubMed ID: 38759899
[TBL] [Abstract][Full Text] [Related]
13. Glycoproteomics Technologies in Glycobiotechnology.
Alagesan K; Hoffmann M; Rapp E; Kolarich D
Adv Biochem Eng Biotechnol; 2021; 175():413-434. PubMed ID: 33205259
[TBL] [Abstract][Full Text] [Related]
14. Physicochemical Characterization, Glycosylation Pattern and Biosimilarity Assessment of the Fusion Protein Etanercept.
Montacir O; Montacir H; Springer A; Hinderlich S; Mahboudi F; Saadati A; Parr MK
Protein J; 2018 Apr; 37(2):164-179. PubMed ID: 29411222
[TBL] [Abstract][Full Text] [Related]
15. Analytical platform for glycomic characterization of recombinant erythropoietin biotherapeutics and biosimilars by MS.
Oh MJ; Hua S; Kim BJ; Jeong HN; Jeong SH; Grimm R; Yoo JS; An HJ
Bioanalysis; 2013 Mar; 5(5):545-59. PubMed ID: 23425271
[TBL] [Abstract][Full Text] [Related]
16. Site-specific protein glycosylation analysis with glycan isomer differentiation.
Hua S; Nwosu CC; Strum JS; Seipert RR; An HJ; Zivkovic AM; German JB; Lebrilla CB
Anal Bioanal Chem; 2012 May; 403(5):1291-302. PubMed ID: 21647803
[TBL] [Abstract][Full Text] [Related]
17. Decoding of O-Linked Glycosylation by Mass Spectrometry.
Mulagapati S; Koppolu V; Raju TS
Biochemistry; 2017 Mar; 56(9):1218-1226. PubMed ID: 28196325
[TBL] [Abstract][Full Text] [Related]
18. Site-specific N-glycosylation analysis of human thyroid thyroglobulin by mass spectrometry-based Glyco-analytical strategies.
Kayili HM; Salih B
J Proteomics; 2022 Sep; 267():104700. PubMed ID: 35995381
[TBL] [Abstract][Full Text] [Related]
19. Data-independent oxonium ion profiling of multi-glycosylated biotherapeutics.
Madsen JA; Farutin V; Lin YY; Smith S; Capila I
MAbs; 2018 Oct; 10(7):968-978. PubMed ID: 30067433
[TBL] [Abstract][Full Text] [Related]
20. Application of a Quantitative LC-MS Multiattribute Method for Monitoring Site-Specific Glycan Heterogeneity on a Monoclonal Antibody Containing Two N-Linked Glycosylation Sites.
Wang T; Chu L; Li W; Lawson K; Apostol I; Eris T
Anal Chem; 2017 Mar; 89(6):3562-3567. PubMed ID: 28199092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
